March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
African Descent and Glaucoma Evaluation Study (ADAGES): Ancestry Differences in Regional Rates of Visual Field Change in Eyes with Glaucomatous Optic Neuropathy
Author Affiliations & Notes
  • Gustavo V. De Moraes
    Ophthalmology, New York Univ School of Med, New York, New York
  • Jeffrey M. Liebmann
    Ophthalmology, New York Univ School of Med, New York, New York
  • Robert Ritch
    Ophthalmology, New York Eye & Ear Infirmary, New York, New York
  • Joseph L. Simonson
    Ophthalmology, New York Eye & Ear Infirmary, New York, New York
  • Christopher Bowd
    Ophthalmology, UCSD Hamilton Glaucoma Center, San Diego, California
  • Pamela A. Sample
    Hamilton Glaucoma Center,
    Univ of California-San Diego, La Jolla, California
  • Christopher A. Girkin
    Ophthalmology, Univ of Alabama at Birmingham, Birmingham, Alabama
  • Felipe A. Medeiros
    Ophthalmology,
    Univ of California-San Diego, La Jolla, California
  • Robert N. Weinreb
    Hamilton Glaucoma Center,
    Univ of California-San Diego, La Jolla, California
  • Linda M. Zangwill
    Ophthalmology,
    Univ of California-San Diego, La Jolla, California
  • Footnotes
    Commercial Relationships  Gustavo V. De Moraes, None; Jeffrey M. Liebmann, Alcon Laboratories Inc., (C), Allergan Inc., (C), Carl Zeiss Meditec Inc., (C), Dyopsis Inc., (F, C), Merz, Inc. (C), Pfizer Inc., (C), Quark, Inc., (C), Topcon Medical Systems Inc. (C), Topcon Medical Systems Inc.. (F); Robert Ritch, Aeon Astron, (C), Drais Pharmaceutical, (C), Dyopsis Inc., (F), iSonic, (C), Medacorp. (C), Ocular Instruments, Inc. (P), Topcon Medical Systems Inc. (F); Joseph L. Simonson, None; Christopher Bowd, None; Pamela A. Sample, Carl Zeiss Meditec Inc., (F), Haag-Streit (F); Christopher A. Girkin, Alcon Laboratories Inc., (C), Allergan Inc., (C), Carl Zeiss Meditec Inc. (R), Heidelberg Engineering GmbH., Optove Inc., Merck Inc., Topcon Medical Systems Inc., Carl Zeiss Meditec Inc. (R), Merck Inc., Topcon Medical Systems Inc., (R), Optovue Inc., (R), Pfizer Inc. (C); Felipe A. Medeiros, Alcon Laboratories Inc., (F, C, R), Allergan Inc., (C, R), Carl Zeiss Meditec Inc., (F, R), Pfizer Inc. (F, C), Pfizer Inc., (R), Reicherts Inc. (R); Robert N. Weinreb, Alcon Laboratories Inc., (C), Allergan Inc., (C), Carl Zeiss Meditec Inc., (F, C), Genentech, (F), Heidelberg Engineering GmbH, (F), Merck Research Laboratories, (C), Nidek, (F), Novartis, (F), Optovue Inc. (C), Optovue Inc., (F), Topcon Medical Systems. (F); Linda M. Zangwill, Carl Zeiss Meditec Inc., (F), Heidelberg Engineering GmbH, (F), Heidelberg Engineering GmbH. (R), Optovue Inc., (F), Topcon Medical Systems Inc. (F)
  • Footnotes
    Support  NEI grants U10EY14267, EY021818, EY11008, EY019869, EY13959; Eyesight F. of Alabama; Alcon Labs. Inc.; Allergan Inc.; Pfizer Inc.; Merck Inc.; Santen Inc.,Corrine Graber Research Fund of the NYGRI
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 263. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gustavo V. De Moraes, Jeffrey M. Liebmann, Robert Ritch, Joseph L. Simonson, Christopher Bowd, Pamela A. Sample, Christopher A. Girkin, Felipe A. Medeiros, Robert N. Weinreb, Linda M. Zangwill; African Descent and Glaucoma Evaluation Study (ADAGES): Ancestry Differences in Regional Rates of Visual Field Change in Eyes with Glaucomatous Optic Neuropathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):263.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Individuals of European (ED) and African (AD) descent have been shown to differ significantly with respect to topographic structural and functional measurements.[1,2] We investigated differences in regional rates of visual field (VF) change between eyes of people of ED and AD eyes with glaucomatous optic neuropathy (GON).

 
Methods:
 

This was an observational cohort study including 842 eyes of 443 patients (273 ED and 170 AD) recruited from the Diagnostic Innovations in Glaucoma Study (DIGS) and the African Descent and Glaucoma Study (ADAGES). We included eyes with GON with at least 5 standard automated perimetry VF tests (SITA 24-2 strategy). To asses topographic rates of progression, we divided the 24-2 VF test output into 6 regions based on the Garway-Heath map.[3] Rates of VF change (dB/yr) were calculated using linear regression with ordinary least square estimates providing the slopes (rate of change) and their statistical significance (P-value) for each region. Significant progression was defined if the regional slopes were worse than -1.0 dB/yr at P <0.01. We compared the mean regional slopes and the number of eyes meeting the progression definition between ED and AD groups.

 
Results:
 

The mean ± SD for the number of VF tests was 10.5±3.8 and 9.4±3.4 for ED and AD eyes respectively (P0.25, GEE). The number of VF regions meeting the progression definition also did not differ between groups (all P-values >0.10, Fisher’s exact test).

 
Conclusions:
 

Consistent with our previous report assessing global rates of change (MD and VFI),[4] ED and AD patients with GON do not show significant differences in regional rates of progressive VF loss.

 
Clinical Trial:
 

http://www.clinicaltrials.gov NCT00221923

 
Keywords: perimetry • visual fields • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×